Jiangsu Hengrui Medicine Co., Ltd
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- -
- Established
- 1970-01-01
- Employees
- -
- Market Cap
- $38.9B
A Safety Study of Multiple Subcutaneous (s.c.) Injections of SHR-1314 in Adults With Moderate-to-severe Plaque Psoriasis
Phase 1
- Conditions
- Moderate-to-severe Plaque Psoriasis
- Interventions
- Biological: SHR-1314
- First Posted Date
- 2018-10-18
- Last Posted Date
- 2018-10-18
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 16
- Registration Number
- NCT03710681
- Locations
- 🇨🇳
Huanshan Hospital , Shanghai Fudan University, Shanghai, China
Study of Carboplatin Plus Etoposide With or Without SHR-1316 in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)
Phase 3
- Conditions
- Extensive-stage Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2018-10-18
- Last Posted Date
- 2022-04-18
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 462
- Registration Number
- NCT03711305
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳Jilin Cancer Hospital, Jilin, Changchun, China
A Study of SHR-1210 Plus Apatinib in Patients With Soft Tissue Sarcoma
Phase 2
Terminated
- Conditions
- Sarcoma
- Interventions
- First Posted Date
- 2018-10-18
- Last Posted Date
- 2024-02-29
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 99
- Registration Number
- NCT03711279
- Locations
- 🇨🇳
Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, Shanghai, China
SHR-1701 in Metastatic or Locally Advanced Solid Tumors
- First Posted Date
- 2018-10-18
- Last Posted Date
- 2021-11-22
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 206
- Registration Number
- NCT03710265
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
Phase III Study of Camrelizumab in Combination With Chemotherapy in Recurrent/Metastatic Nasopharyngeal Carcinoma
Phase 3
- Conditions
- Nasopharyngeal Carcinoma
- Interventions
- First Posted Date
- 2018-10-16
- Last Posted Date
- 2022-07-01
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 263
- Registration Number
- NCT03707509
- Locations
- 🇨🇳
Cancer Center of Sun-Yat Sen University (CCSYSU), Guangzhou, Guangdong, China
Safety, Tolerability and PK of SHR1314 in axSpA
- First Posted Date
- 2018-10-12
- Last Posted Date
- 2021-01-13
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 45
- Registration Number
- NCT03704428
- Locations
- 🇨🇳
Jianwen Chen, Shanghai, China
Study of SHR-1210 in Combination With Chemotherapy in Advanced Esophageal Cancer
Phase 3
Completed
- Conditions
- Advanced Esophageal Cancer
- Interventions
- First Posted Date
- 2018-10-01
- Last Posted Date
- 2022-12-07
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 596
- Registration Number
- NCT03691090
- Locations
- 🇨🇳
Cancer Center of Sun-Yat Sen University (CCSYSU), Guangzhou, Guangdong, China
Safety, Tolerability and PK/PD of SHR1459 in Healthy Volunteers
- First Posted Date
- 2018-09-12
- Last Posted Date
- 2018-09-12
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT03668509
- Locations
- 🇨🇳
Xu qian, M.D. Ph.D, Shanghai, China
A Study of SHR-1210 in Combination With Carboplatin + Paclitaxel in Subjects With Squamous NSCLC
Phase 3
- Conditions
- Lung Cancer Squamous CellLung Cancer Stage IVPD-1 AntibodyChemotherapy Effect
- Interventions
- Drug: The placebo
- First Posted Date
- 2018-09-12
- Last Posted Date
- 2021-03-15
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 390
- Registration Number
- NCT03668496
- Locations
- 🇨🇳
Anhui Provincial Hospital, Hefei, Anhui, China
🇨🇳Anhui Chest Hospital, Hefei, Anhui, China
🇨🇳Beijing Cancer Hospital, Beijing, Beijing, China
A Study of SHR-1210 in Combination With BP102 in Subjects With Non-squamous NSCLC
- First Posted Date
- 2018-09-12
- Last Posted Date
- 2021-03-17
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 5
- Registration Number
- NCT03666728
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
© Copyright 2025. All Rights Reserved by MedPath